Exchange: NASDAQ·Updated 03:15 PM EST

SPRO News

News
all
press releases
SPRO Stock Gets Stronger EPS Estimate from HC Wainwright
Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - HC Wainwright boosted their Q4 2026 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Selvaraju now expects that the company will pos...
MarketBeat
SPRO Stock Gets Stronger EPS Estimate from HC Wainwright
Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - HC Wainwright boosted their Q4 2026 earnings per share (EPS) estimates for Spero Therapeutics in a research report issued to clients and investors on Monday, November 16th. HC Wainwright analyst R. Selvaraju now expects that the company will pos...
MarketBeat
More News
Wall Street Zen downgraded Spero Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday...
MarketBeat
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
(RTTNews) - Spero Therapeutics, Inc. (SPRO), a clinical-stage biopharmaceutical company, on Monday said it has appointed Debra Jeske Zack as Chief Medical Officer...
Nasdaq News: Markets
Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody Innovent Biologics and Spero Therapeutics Announce Exclusive License for IBI355 (SP001), a Phase 2-Ready Third-Generation Anti-CD40L Antibody PR Newswire SAN...
PR Newswire
The healthcare and biotechnology sector continues to generate a steady stream of meaningful catalysts as companies advance novel therapies, secure regulatory milestones, strengthen intellectual property portfolios, and expand commercialization efforts. Recent developments from CervoMed (NASDAQ:CRVO), Butterfly Network (NYSE:BFLY), NeOnc (NASDAQ:NTHI), Spero Therapeutics (NASDAQ:SPRO), GSK (NYSE:GSK), and IceCure Medical (NASDAQ:ICCM) highlight several emerging themes shaping the sector, including neurodegenerative disease treatment, AI-powered diagnostics, antimicrobial resistance, minimally invasive cancer care, and synthetic biology.
24-7 Market News
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Zacks
GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs) including pyelonephritisi, caused by certain susceptible pathogensii...
Business Wire
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to its Board of Directors at the annual general meeting of shareholders. Ms. Tregoning is expected...
Business Wire
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totaling 737,720...
MarketBeat

Advertisement|Remove ads.